Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: A systematic review

Mayo Clinic Proceedings

Volumn 82, Issue 2, 2007, Pages 159-165

  Garza, Carolina A ^a   Montori, Victor M ^a   McConnell, Joseph P ^a   Somers, Virend K ^a   Kullo, Iftikhar J ^a   Lopez Jimenez, Francisco ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIPOPROTEIN; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2; PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEART DEATH; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; IMMUNOASSAY; META ANALYSIS; REVIEW; RISK REDUCTION; SYSTEMATIC REVIEW;

EID: 33846658406     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.2.159     Document Type: Article

References (38)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Dallas, Tex: American Heart Association; 2005.
2. Peyser PA, Bielak LF, Chu JS, et al. Heritability of coronary artery calcium quantity measured by electron beam computed tomography in asymptomatic adults. Circulation. 2002;106:304-308.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men [published correction appears in N Engl J Med. 1997;337:356]. N Engl J Med. 1997;336:973-979.
4. Macphee CH. Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Curr Opin Pharmacol. 2001;1:121-125.
5. Asano K, Okamoto S, Fukunaga K, et al. Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma. Biochem Biophys Res Commun. 1999;261:511-514.
6. Caslake MJ, Packard CJ, Suckling KE, Holmes SD, Chamberlain P, Macphee CH. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase: a potential new risk factor for coronary artery disease. Atherosclerosis. 2000;150:413-419.
7. Dada N, Kim NW, Wolfert RL. Lp-PLA2: an emerging biomarker of coronary heart disease. Expert Rev Mol Diagn. 2002;2:17-22.
8. Quinn MT, Parthasarathy S, Steinberg D. Lysophosphatidylcholine: a chemotactic factor for human monocytes and its potential role in atherogenesis. Proc Natl Acad Sci U S A. 1988;85:2805-2809.
9. Carpenter KL, Dennis IF, Challis IR, et al. Inhibition of lipoprotein-associated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett. 2001;505:357-363.
10. Yamada Y, Ichihara S, Fujimura T, Yokota M. Identification of the G994→T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metabolism. 1998;47:177-181.
11. Yamada Y, Yoshida H, Ichihara S, Imaizumi T, Satoh K, Yokota M. Correlations between plasma platelet-activating factor acetylhydrolase (PAF-AH) activity and PAF-AH genotype, age, and atherosclerosis in a Japanese population. Atherosclerosis. 2000;150:209-216.
12. Yamamoto I, Fujitsu J, Nohnen S, et al. Association of plasma PAF acetylhydrolase gene polymorphism with IMT of carotid arteries in Japanese type 2 diabetic patients. Diabetes Res Clin Pract. 2003;59:219-224.
13. Tselepis AD, Chapman MJ. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3:57-68.
14. Tsaoussis V, Vakirtzi-Lemonias C. The mouse plasma PAF acetylhydrolase, II: it consists of two enzymes both associated with the HDL. J Lipid Mediat Cell Signal. 1994;9:317-331.
15. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: www.ohri.ca/programs/clinical_epidemiology/oxford.htm. Accessed January 3, 2007.
16. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-560.
17. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219.
18. O'Donoghue M, Morrow DA, Sabatine MS, et al. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation. 2006 Apr 11;113:1745-1752. Epub 2006 Mar 14.
19. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302-1306.
20. Packard CJ, O'Reilly DS, Caslake MJ, et al, West of Scotland Coronary Prevention Study Group. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
21. Ballantyne CM, Hoogeveen RC, Bang H, et al. Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation. 2004 Feb 24;109:837-842. Epub 2004 Feb 2.
22. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004 Oct 5;110:1903-1908. Epub 2004 Sep 27.
23. Blankenberg S, Stengel D, Rupprecht HJ, et al. Plasma PAF-acetylhydrolase in patients with coronary artery disease: results of a cross-sectional analysis. J Lipid Res. 2003 Jul;44:1381-1386. Epub 2003 May 1.
24. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J. 2005 jan;26:137-144. Epub 2004 Nov 29.
25. 2 independently predicts the angiographic diagnosis of coronary artery disease [abstract]. J Am Coll Cardiol. 2005;45(suppl A):224A. Abstract 814-7.
26. Oei HH, van der Meer IM, Hofman A, et al. Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570-575.
27. Winkler K, Winkelmann BR, Scharnagl H, et al. Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study [published correction appears in Circulation. 2005;111:e444]. Circulation. 2005 Mar 1;111:980-987. Epub 2005 Feb 14.
28. 2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis. Atherosclerosis. 2005 Sep;182:181-188. Epub 2005 Apr 14.
29. Persson M, Nilsson J-A, Hedblad B, Nelson JJ, Berglund G. Lipoprotein-associated phospholipase A2 predicts cardiovascular events [abstract]. Presented at: Scientific Sessions 2005 of the American Heart Association; Dallas, Tex; November 13-16, 2005.
30. Koenig W, Twardella D, Brenner H, Rothenbacher D. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006 Jul;26:1586-1593. Epub 2006 Apr 20.
31. Gerber Y, McConnell JP, Jaffe AS, Weston SA, Killian JM, Roger VL. Lipoprotein-associated phospholipase A2 and prognosis after myocardial infarction in the community. Arterioscler Thromb Vasc Biol. 2006 Nov;26:2517-2522. Epub 2006 Aug 10.
32. Corsetti JP, Rainwater DL, Moss AJ, Zareba W, Sparks CE. High lipoprotein-associated phospholipase A2 is a risk factor for recurrent coronary events in postinfarction patients. Clin Chem. 2006 Jul;52:1331-1338. Epub 2006 May 18.
33. Sudhir K. Clinical review: lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. J Clin Endocrinol Metab. 2005 May;90:3100-3105. Epub 2005 Feb 15.
34. Hakkinen T, Luoma JS, Hiltunen MO, et al. Lipoprotein-associated phospholipase A(2), platelet-activating factor acetylhydrolase, is expressed by macrophages in human and rabbit atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 1999;19:2909-2917.
35. Singh U, Zhong S, Xiong M, Li TB, Sniderman A, Teng BB. Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice. Clin Sci (Lond). 2004;106:421-432.
36. Memon RA, Fuller J, Moser AH, Feingold KR, Grunfeld C. In vivo regulation of plasma platelet-activating factor acetylhydrolase during the acute phase response. Am J Physiol. 1999;277(1, pt 2):R94-R103.
37. Iribarren C, Gross MD, Darbinian JA, Jacobs Dr Jr, Sidney S, Loria CM. Association of lipoprotein-associated phospholipase A2 mass and activity with calcified coronary plaque in young adults: the CARDIA study. Arterioscler Thromb Vasc Biol. 2005 Jan;25:216-221. Epub 2004 Oct 21.
38. Danesh J, Wheeler JG, Hirschfield GM, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.